blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3807272

EP3807272 - BIFUNCTIONAL MOLECULES FOR TARGETING RPN11 [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  21.01.2022
Database last updated on 07.10.2024
FormerRequest for examination was made
Status updated on  19.03.2021
FormerThe international publication has been made
Status updated on  21.12.2019
Formerunknown
Status updated on  08.07.2019
Most recent event   Tooltip10.09.2024New entry: Application deemed to be withdrawn: despatch of communication + time limit 
Applicant(s)For all designated states
Amphista Therapeutics Ltd
The Cori Building Granta Park
Great Abington, Cambridge CB21 6GQ / GB
[2023/04]
Former [2021/16]For all designated states
Amphista Therapeutics Ltd
158-160 North Gower Street
London NW1 2ND / GB
Inventor(s)01 / CIULLI, Alessio
11 Step Row
Dundee DD2 1AF / GB
02 / TESTA, Andrea
c/o Amphista Therapeutics Ltd.
Bo'Ness Road
Newhouse, North Lanarkshire ML1 5UH / GB
03 / HUGHES, Scott
c/o Amphista Therapeutics Ltd.
Bo'Ness Road
Newhouse, North Lanarkshire ML1 5UH / GB
04 / BUTCHER, Steven Peter
23 Spaldwick Road
Stow Longa
Huntingdon, Cambridgeshire PE28 0TL / GB
 [2021/16]
Representative(s)Goodacre, Jonathan David
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
[N/P]
Former [2021/16]Rudkin, Mairi Ellen
Marks & Clerk LLP
Aurora
120 Bothwell Street
Glasgow G2 7JS / GB
Application number, filing date19733978.113.06.2019
[2021/16]
WO2019EP65481
Priority number, dateUS201862684265P13.06.2018         Original published format: US 201862684265 P
US201962835953P18.04.2019         Original published format: US 201962835953 P
[2021/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019238817
Date:19.12.2019
Language:EN
[2019/51]
Type: A1 Application with search report 
No.:EP3807272
Date:21.04.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 19.12.2019 takes the place of the publication of the European patent application.
[2021/16]
Search report(s)International search report - published on:EP19.12.2019
ClassificationIPC:C07D417/14, C07D495/14, C07D417/12, A61K31/4439, A61K31/444, A61K31/506, A61K31/5517, A61P7/06, A61P35/00
[2021/16]
CPC:
C07D495/14 (EP,KR,US); C07D417/14 (EP,KR,US); A61K47/60 (US);
A61K31/277 (US); A61K31/351 (US); A61K31/404 (US);
A61K31/407 (US); A61K31/4184 (US); A61K31/423 (US);
A61K31/428 (US); A61K31/4375 (US); A61K31/44 (US);
A61K31/47 (US); A61K31/4709 (US); A61K31/496 (US);
A61K31/506 (US); A61K31/519 (US); A61K31/5355 (US);
A61K31/551 (US); A61K47/55 (EP,KR,US); A61K47/555 (KR);
A61P35/00 (EP,KR); A61P7/06 (EP,KR); C07D417/12 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/16]
TitleGerman:BIFUNKTIONALE MOLEKÜLE ZUM TARGETING VON RPN11[2021/16]
English:BIFUNCTIONAL MOLECULES FOR TARGETING RPN11[2021/16]
French:MOLÉCULES BIFONCTIONNELLES POUR CIBLER RPN11[2021/16]
Entry into regional phase24.11.2020National basic fee paid 
24.11.2020Designation fee(s) paid 
24.11.2020Examination fee paid 
Examination procedure24.11.2020Examination requested  [2021/16]
24.11.2020Date on which the examining division has become responsible
28.07.2021Amendment by applicant (claims and/or description)
20.01.2022Despatch of a communication from the examining division (Time limit: M06)
01.08.2022Reply to a communication from the examining division
16.01.2023Despatch of a communication from the examining division (Time limit: M06)
25.07.2023Reply to a communication from the examining division
23.02.2024Despatch of a communication from the examining division (Time limit: M06)
09.09.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
Fees paidRenewal fee
29.07.2021Renewal fee patent year 03
13.05.2022Renewal fee patent year 04
12.05.2023Renewal fee patent year 05
31.03.2024Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
30.06.202103   M06   Fee paid on   29.07.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO9320094  (ABBOTT LAB [US], et al) [X] 1-7,15-30,38,39,44-47 * examples 4, 6, 9 10, 14-29; claims 15-21, 24, 25, 37, 38 *;
 [Y]US5521184  (ZIMMERMANN JUERG [CH]) [Y] 1-7,15-30,38-47 * example 21; claims 1-23 *;
 [Y]WO0062778  (BRISTOL MYERS SQUIBB CO [US]) [Y] 1-7,15-30,38-47 * claims 1-58; compounds 455, 457 *;
 [Y]EP2199283  (KOWA CO [JP]) [Y] 1-7,15-30,38-47 * Compounds 8, 15, 27, 41-43, 45, 54, 93, 95, 97, 100, 113-121;; claims 1-20 *;
 [A]WO2017031255  (CALIFORNIA INST OF TECHN [US]) [A] 1-7,15-30,38-47 * claims 1-20 *;
 [X]WO2017046036  (GLAXOSMITHKLINE IP DEV LTD [GB]) [X] 1-7,15-30,38,39,44-47 * examples 1, 13, 23, 26; claims 1-20 *;
 [X]WO2017182418  (GLAXOSMITHKLINE IP DEV LTD [GB]) [X] 1-7,15-30,38,39,44-47 * page 89 last compound, page 90 first compound, page 97 the two compounds, page 142 first compound;; claims 1-18 *;
 [X]  - DANIEL P BONDESON ET AL, "Catalytic in vivo protein knockdown by small-molecule PROTACs", NATURE CHEMICAL BIOLOGY, (20150101), vol. 11, no. 8, pages 611 - 617, XP055621789 [X] 1-7,15-30,38,39,44-47 * PROTAC_RIPK2; page 612; figures 1-5 *
 [Y]  - PANAGIS FILIPPAKOPOULOS ET AL, "Selective inhibition of BET bromodomains", NATURE, London, (20101201), vol. 468, no. 7327, doi:10.1038/nature09504, ISSN 0028-0836, pages 1067 - 1073, XP055589157 [Y] 1-7,15-30,38-47 * figures 1-5; compounds JQ-1 *

DOI:   http://dx.doi.org/10.1038/nature09504
by applicantUS4522811
 WO0222577
 US6468798
 US7208157
 US2010137254
 US2010183742
 WO2012078559
 WO2013106643
 US2016176916
 WO2016146985
 WO2017024318
 WO2017024317
 WO2017024319
 US2017050931
 US9670482
    - BULATOV et al., Biochem J., (20150000), vol. 467, pages 365 - 386
    - LI et al., PLOS One, (20080000), vol. 3, page 1487
    - BERNDSEN et al., Nat. Struct. Mol. Biol., (20140000), vol. 21, pages 301 - 307
    - DESHAIES et al., Ann. Rev. Biochem., (20090000), vol. 78, pages 399 - 434
    - SPRATT et al., Biochem., (20140000), vol. 458, pages 421 - 437
    - WANG et al., Nat. Rev. Cancer.,, (20140000), vol. 14, pages 233 - 347
    - OTTIS, P.CREWS, C. M., "Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy", ACS Chem Biol, (20170000), vol. 12, pages 892 - 898
    - HOGAN et al., Handbook Of Experimental Immunology, Cold Spring Harbor Laboratory Press, (19860000), vol. I-IV
    - PEREZ et al., J. Med. Chem., (20170000), vol. 60, pages 1343 - 1361
    - FINNIN, M. S. et al., "Structures of Histone Deacetylase Homologue Bound to the TSA and SAHA Inhibitors", Nature, (19990000), vol. 40, doi:doi:10.1038/43710, pages 188 - 193, XP002266214

DOI:   http://dx.doi.org/10.1038/43710
    - O' CONNOR et al., Nat Protoc., (20160400), vol. 11, no. 4, pages 781 - 94
    - SUN et al., Clin Cancer Res., (20120201), vol. 18, no. 3, pages 758 - 70
    - SCHENKEL et al., "Discovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors", J. Med. Chem., (20110000), vol. 54, no. 24, doi:doi:10.1021/jm200911r, pages 8440 - 8450, XP055043479

DOI:   http://dx.doi.org/10.1021/jm200911r
    - SUN et al., Mol. Pharmaceutics, (20180000), vol. 15, pages 3343 - 3355
    - ZHANG et al., European Journal of Pharmaceutics and Biopharmaceutics, (20180000), vol. 128, pages 260 - 271
    - MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 552 - 554
    - TSUCHIKAMA et al., Protein Cell, (20180000), vol. 9, no. 1, pages 33 - 46
    - WANG et al., J. Am. Chem. Soc., (20140000), vol. 136, pages 2731 - 2734
    - JONES et al., "Small-Molecule Kinase Downregulators", Cell Chem. Biol., (20170000), vol. 25, pages 30 - 35
    - ROMERO, F.A.TAYLOR, A.M.CRAWFORD, T. D.TSUI, V.COTE, A.MAGNUSON, S., "Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors", J. Med. Chem., (20160000), vol. 59, no. 4, doi:doi:10.1021/acs.jmedchem.5b01514, pages 1271 - 1298, XP055302035

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.5b01514
    - MILLAN et al., "Design and Synthesis of Inhaled P38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease", Med. Chem., (20110000), vol. 54, doi:doi:10.1021/jm200677b, page 7797, XP055150024

DOI:   http://dx.doi.org/10.1021/jm200677b
    - VAN EIS et al., "2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes", Biorg. Med. Chem. Lett., (20111200), vol. 21, no. 24, doi:doi:10.1016/j.bmcl.2011.10.025, pages 7367 - 72, XP028113889

DOI:   http://dx.doi.org/10.1016/j.bmcl.2011.10.025
    - LOUNTOS et al., "Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy", J. Struct.. Biol., (20110000), vol. 176, doi:doi:10.1016/j.jsb.2011.09.008, page 292, XP028104277

DOI:   http://dx.doi.org/10.1016/j.jsb.2011.09.008
    - LOUNTOS et al., "Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy", J. Struct. Biol., (20110000), vol. 176292
    - HEWINGS et al., "3,5-Dimethylisoxazoles Act as Acetyl-lysine Bromodomain Ligands", J. Med. Chem., (20110000), vol. 54, doi:doi:10.1021/jm200640v, pages 6761 - 6770, XP002689396

DOI:   http://dx.doi.org/10.1021/jm200640v
    - VASSILEV et al., "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2", Science, (20040000), pages 303844 - 848
    - SCHNEEKLOTH et al., "Targeted intracellular protein degradation induced by a small molecule: En route to chemicalproteomics", Biorg. Med. Chem. Lett., (20080000), vol. 18, doi:doi:10.1016/j.bmcl.2008.07.114, pages 5904 - 5908, XP025627166

DOI:   http://dx.doi.org/10.1016/j.bmcl.2008.07.114
    - VALLEE et al., "Tricyclic Series of Heat Shock Protein 90 (HSP90) Inhibitors Part I: Discovery of Tricyclic Imidazo [4,5-C] Pyridines as Potent Inhibitors of the HSP90 Molecular Chaperone", Med. Chem., (20110000), vol. 54, doi:doi:10.1021/jm200784m, page 7206, XP055240728

DOI:   http://dx.doi.org/10.1021/jm200784m
    - BROUGH et al., "4,5-Diarylisoxazole HSP90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer", Med. Chem., (20080000), vol. 51, page 196
    - WRIGHT et al., "Structure- Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms", Chem Biol., (20040600), vol. 11, no. 6, doi:doi:10.1016/j.chembiol.2004.03.033, pages 775 - 85, XP025940200

DOI:   http://dx.doi.org/10.1016/j.chembiol.2004.03.033
    - CHANG et al., "Structural Basis for G9a-Like protein Lysine Methyltransferase Inhibition by BIX-1294", Nat. Struct. Biol., (20090000), vol. 16, no. 3, page 312
    - LIU, F. et al., "Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Methyltransferase G9a", J. Med. Chem., (20090000), vol. 52, no. 24, doi:doi:10.1021/jm901543m, page 7950, XP002702501

DOI:   http://dx.doi.org/10.1021/jm901543m
    - SAKAMOTO et al., "Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation", Mol. Cell Proteomics, (20031200), vol. 2, no. 12, doi:doi:10.1074/mcp.T300009-MCP200, pages 1350 - 1358, XP055039869

DOI:   http://dx.doi.org/10.1074/mcp.T300009-MCP200
    - RODRIGUEZ-GONZALEZ et al., "Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer", Oncogene, (20080000), vol. 27, doi:doi:10.1038/onc.2008.320, pages 7201 - 7211, XP055001566

DOI:   http://dx.doi.org/10.1038/onc.2008.320
    - SAKAMOTO et al., "Protacs: chimeric molecules that target proteins to the Skpl- Cullin-F box complex for ubiquitination and degradation", Proc. Natl. Acad. Sci. USA, (20010700), vol. 98, no. 15, pages 8554 - 8559
    - SCHNEEKLOTH et al., "Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation", J. Am. Chem. Soc., (20040000), vol. 126, doi:doi:10.1021/ja039025z, pages 3748 - 3754, XP008141514

DOI:   http://dx.doi.org/10.1021/ja039025z
    - LEE et al., "Targeted Degradation of the Aryl Hydrocarbon Receptor by the PROTAC Approach: A Useful Chemical Genetic Tool", ChemBioChem, (20071123), vol. 8, no. 17, pages 2058 - 2062
    - BOITANO et al., "Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells", Science, (20100900), vol. 329, no. 5997, doi:doi:10.1126/science.1191536, pages 1345 - 1348, XP055545288

DOI:   http://dx.doi.org/10.1126/science.1191536
    - J. Med. Chem., (20100000), vol. 53, pages 6466 - 538
    - Angew. Chem. Int. Ed., (20110000), vol. 50, pages 9838 - 9842
    - MCCAFFREY et al., Nature, (20020000), vol. 418, no. 6893, pages 38 - 9
    - XIA et al., Nature Biotechnol., (20020000), vol. 20, no. 10, pages 1006 - 10
    - PUTNAM, Am. J. Health Syst. Pharm., (19960000), vol. 53, no. 3, pages 325 - 160
    - WESTERFIELD, M., The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio, Univ. of Oregon Press, (20000000), vol. 154 and 155
 WO2012US63401
 WO2015US25813
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.